Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura King

Physician Assistant Royal Oak, MI Physician Assistant

NPI 1174922694 CMS profile 10783611

4630 Elmwood Avenue, Royal Oak, MI 48073

Open in the dashboard

General payments

$62,550

242 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura King of Royal Oak, MI is reported in the CMS Open Payments database as having received $62,550 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,262 91
2024 General $20,141 59
2023 General $8,259 46
2022 General $3,269 28
2021 General $619 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura King
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Laura King were reported at $30,262. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Laura King Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $619 $132 $37–$438 $132
2022 $3,269 $155 $48–$522 $149
2023 $8,259 $167 $52–$557 $160
2024 $20,141 $178 $55–$600 $164
2025 $30,262 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $57,742 144 payments
  2. Medtronic, Inc. $2,736 67 payments
  3. Abiomed $380 3 payments
  4. Kestra Medical Technology Services, Inc. $351 6 payments
  5. Biotronik Inc. $265 4 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $189 4 payments
  7. Philips Electronics North America Corporation $132 1 payment
  8. Novo Nordisk Inc $113 1 payment
  9. Impel Pharmaceuticals Inc. $107 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $107 1 payment
  11. Other $427 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,900 30 payments
  2. Travel and Lodging $15,509 57 payments
  3. Food and Beverage $10,941 154 payments
  4. Consulting Fee $1,200 1 payment
Products named General payments · program years 2021–2025
  1. WATCHMAN Access System $26,435 44 payments
  2. General - Therapies $9,796 24 payments
  3. LUX-Dx Insertable Cardiac Monitor $8,971 27 payments
  4. WATCHMAN FLX $2,707 12 payments
  5. EMBLEM MRI S-ICD $2,509 8 payments
  6. Micra $1,001 21 payments
  7. COBALT DR MRI SURESCAN $393 13 payments
  8. Impella $253 2 payments
  9. Acticor 7 VR-T DX $223 3 payments
  10. Assure WCD $194 4 payments
  11. Other $2,432 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

396

Median for Physician Assistant: 241

Drug cost

$153,922

Median for Physician Assistant: $4,110

Branded share of claims

33.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 88 $113,287
Xarelto Rivaroxaban Brand 16 $18,419
Quinidine Gluconate Generic 16 $11,237
Amiodarone Hcl Generic 58 $4,216
Dofetilide Generic 30 $2,915
Flecainide Acetate Generic 22 $1,392
Metoprolol Succinate Generic 63 $880
Sotalol Sotalol Hcl Brand 14 $530
Metoprolol Tartrate Generic 41 $384
Clopidogrel Clopidogrel Bisulfate Brand 13 $335

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$9,505

Medicare's payments for the services billed

Medicare patients

92

Average age 73

Services billed

176

36 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Heart failure 74%
Ischemic heart disease 66%
Diabetes 54%
Chronic kidney disease 50%
Arthritis 40%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record